Evidence map›Paper›PMID 38510131›Full record

ArticleiScience2024

MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma.

Lama Hasan Bou Issa, Léa Fléchon, William Laine, Aicha Ouelkdite, Silvia Gaggero, Adeline Cozzani, Remi Tilmont, Paul Chauvet, Nicolas Gower, Romanos Sklavenitis-Pistofidis and 8 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Lama Hasan Bou IssaCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Léa FléchonCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
William LaineCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Aicha OuelkditeCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Silvia GaggeroCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Adeline CozzaniCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Remi TilmontDepartment of Hematology, CHU Lille, 59000 Lille, France.
Paul ChauvetDepartment of Hematology, CHU Lille, 59000 Lille, France.
Nicolas GowerDepartment of Hematology, CHU Lille, 59000 Lille, France.
Romanos Sklavenitis-PistofidisDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Carine BrinsterCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Xavier ThuruCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Yasmine TouilCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Bruno QuesnelCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Suman MitraCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Irene M GhobrialDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Jérôme KluzaCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Salomon ManierCanther, INSERM UMR-S1277 and CNRS UMR9020, Lille University, 59000 Lille, France.
Inserm · FRCentre Hospitalier Universitaire de Lille · FRCentre National de la Recherche Scientifique · FRUniversité de Lille · FRHarvard University · USLille’s Cardiology Hospital · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is an incurable hematological malignancy in which MYC alterations contribute to the malignant phenotype. Nevertheless, MYC lacks therapeutic druggability. Here, we leveraged large-scale loss-of-function screens and conducted a small molecule screen to identify genes and pathways with enhanced essentiality correlated with

Indexed as

CancerMetabolomicsTranscriptomics

Identifiers

PMID38510131
PMCPMC10952034
OpenAlexW4392368731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.